



Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

Abdominal contour procedures, **475–493**

- after gastric bypass surgery, 488
- anatomy in, 475–476
- complications of, 488, 492
- in obese patients, 486, 488
- patient consultation and evaluation for, 476–477
- techniques for, 477–482
 - full abdominoplasty with or without suction-assisted lipectomy, 481–482
 - mini-abdominoplasty, 480
 - minimal access abdominoplasty, 482–486
 - endoscopically assisted or muscle access abdominoplasty, 485–486
 - extended liposuction, 483–484
 - open mini-abdominoplasty, 484–485
 - modified abdominoplasty, 480–481
 - suction-assisted lipectomy, 478–480

Abdominoplasty. *See* Abdominal contour procedures.

Ablative facial resurfacing, **549–559**

- chemical peels in, 370, 550–552
 - agents in, 550–551
 - postoperative care for, 552
 - technique for, 551–552
- combined procedures in, 554
- complications of, 555–559
 - erythema, 558
 - hyperpigmentation, 557–558
 - hypopigmentation, 557
 - milia, 557
 - scars, 558
- dermabrasion in, 552–553
 - instruments for, 552
 - technique for, 552–553
- Fitzpatrick skin type and, 549
- indications for, 549
- lasers in, 553–554
- patient preparation for, 549–550
- patient selection for, 549
- results of, 554–555

Ablative lasers, in surgical revisions, 148–149

Abuse, physical and sexual, and posttraumatic stress disorder, 650–651

Acne. *See also* Acne vulgaris.

- depression with. *See* Depression.
- eating disorders and, 597
- emotional impact of, 623
- isotretinoin for, suicide due to. *See* Suicide.
- photodynamic therapy for, 204–205
- psychosomatic aspects of, 602, 603–604

Acne vulgaris. *See also* Acne.

- cosmetics for, **575–581**
 - cleansers, 576–577
 - corneolytics, 577
 - definition of, 575
 - moisturizers, 577
 - retinol, 577
 - sulfur, 577
- versus anti-acne drugs, 575–576
- weeks 1 to 4, 577–578
- weeks 4 to 8, 578
- weeks 8 to 12, 578
- weeks 12 to 16, 578
- weeks 16 to 20, 578–579
- weeks 20 to 24, 579

Actinic cheilitis, imiquimod for, 154

Actinic keratoses, imiquimod for, 152, 154, 249–250
of hands, topical agents for, 516

Acupuncture, in dermatology, 723–724

Acyclovir, indications for, 314–315

Advancement flaps, in auricular reconstruction, 33–38

- in eyebrow reconstruction, 10
- in forehead reconstruction, 4, 7–9
- in lip reconstruction, 46–48, 50–51
- in scalp reconstruction, 19–20

- Aging skin, demographics of, 643
 psychosocial aspects of, **643–648**
 body image, 646–647
 Brief Symptom Inventory of, 644
 business interactions, 645
 caregiver reactions, 645
 Eating Disorder Inventory in, 646
 eating disorders, 646–647
 facial expressions, 644–645
 interpersonal interactions, 644–645
 narcissistic personality, 646
 psychologic state, 645–646
 suicidal ideation, 646
- Aldara. *See* Imiquimod.
- Alefacept. *See* Systemic immune modulators.
- Alexithymia, with psoriasis, 685
- Allogenic fillers, in facial rejuvenation, 367–368
 in soft tissue augmentation, 353
- Alopecia. *See* Hair loss.
- Aminolevulinic acid, in photodynamic therapy, 204
- Amitriptyline, for dermatologic conditions, 743
- Anesthesia, in dermabrasion, 553
 in forehead reconstruction, 2
 in laser therapy, for vascular lesions, 753
 in nasal reconstruction, with dorsal nasal flaps, 78
 with forehead flaps, 89
 in reduction structured rhinoplasty, 533–534
 in rhytidectomy, 418
 topical, in pediatric dermatology, 174
 tumescent, in ambulatory phlebectomy, for
 varicose veins, 447–448
 in follicular unit transplantation, 401
- Angioedema, depression with, 661
- Angiomas, spider, in children, laser therapy for, 750
- Anthralin, for alopecia areata, 237
- Anti-acne drugs, for acne vulgaris, 575–576
- Antiandrogen therapy, for female pattern hair
 loss, 232
- Antibiotics, **301–312**
 dalbavancin and oritavancin, 309
 daptomycin, 301–303
 adverse effects of, 302–303
 clinical data on, 301–302
 historical aspects of, 301
 indications for, 301
 interactions with, 302
 mechanism of action of, 301
 pharmacokinetics and dosing of, 302
 gatifloxacin and moxifloxacin, 307–309
 adverse effects of, 308–309
 clinical data on, 308
 historical aspects of, 307
 indications for, 307–308
 interactions with, 308
 mechanism of action of, 307
 pharmacokinetics and dosing of, 308
 in follicular unit transplantation, 400
 in wound healing, 185, 188
 interactions with, 335–336
 linezolid, 303–306
 adverse effects of, 305–306
 clinical data on, 304
 for diabetic foot ulcers, 189
 historical aspects of, 303
 indications for, 303–304
 interactions with, 304–305
 mechanism of action of, 303
 pharmacokinetics and dosing of, 304
 spectrum of activity of, 303
 quinupristin-dalfopristin, 306–307
 adverse effects of, 307
 clinical data on, 306
 historical aspects of, 306
 indications for, 306
 interactions with, 307
 mechanism of action of, 306
 pharmacokinetics and dosing of, 306–307
- Antidepressants, for anxiety, 740
 for depression, 737–739
 in dermatology, 731
- Antimicrobial dressings, in wound healing, 189–190
- Antioxidant therapy, for hypomelanosis, 216
- Antipsychotic drugs, for delusional disorders, 741
- Antiviral therapy, **313–322**
 acyclovir in, 314–315
 cidofovir in, 316, 318, 319
 experimental vaccines in, 319–320
 for herpesvirus infections, 319
 for human papillomavirus, 319–320
 famciclovir in, 315
 fomivirsen in, 316
 for cytomegalovirus, 314
 for Epstein-Barr virus, 314
 for herpes simplex-1, 313
 for herpes simplex-2, 313–314
 for herpes zoster, 314
 for human papillomavirus, 317–318
 for molluscum contagiosum, 318–319
 foscarnet in, 316–317

Download English Version:

<https://daneshyari.com/en/article/9225088>

Download Persian Version:

<https://daneshyari.com/article/9225088>

[Daneshyari.com](https://daneshyari.com)